The phase I study of Topalian et al. 30in 2012 was performed among 296 patients (including 122 NSCLC patients) previously treated with nivolumab and showed that PD-L1 positive tumors by IHC (performed using the 5H1 clone) had an ORR of 36%, whereas PD-L1 negative tumors did not achieve any ORR. This evidence concerns the gene CD274 and non-small cell lung carcinoma.